Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.

Abstract

Livedoid vasculopathy is characterized by painful purpuric lesions on the extremities which frequently ulcerate and heal with atrophic scarring. For many years, livedoid vasculopathy has been considered to be a primary vasculitic process. However, there has been evidence considering livedoid vasculopathy as an occlusive vasculopathy due to a hypercoagulable state. We present the case of livedoid vasculopathy in a 21-year-old female who had been suffering of painful lower extremity lesions of 3 years duration. The patient was found to be lupus anticoagulant positive and homozygous for methylenetetrahydrofolate reductase C677T mutation. The patient was successfully treated with low-molecular-weight heparin.

• Authors: Jihane Abou Rahal, Rim S Ishak, Zaher K Otrock, Abdul-Ghani Kibbi, Ali T Taher
• Journal: Journal of thrombosis and thrombolysis (J Thromb Thrombolysis) Vol. 34 Issue 4 Pg. 541-4 (Nov 2012) ISSN: 1573-742X [Electronic] Netherlands
• PMID: 22592843 (Publication Type: Case Reports, Letter)

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• Lupus Coagulation Inhibitor
• MTHFR protein, human
• Methylenetetrahydrofolate Reductase (NADPH2)

Topics

• Adult
• Anticoagulants (administration & dosage)
• Female
• Heparin, Low-Molecular-Weight (administration & dosage)
• Humans
• Livedo Reticularis (drug therapy, genetics, pathology)
• Lupus Coagulation Inhibitor
• Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
• Point Mutation